<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01255527</url>
  </required_header>
  <id_info>
    <org_study_id>4-2010-0482</org_study_id>
    <nct_id>NCT01255527</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study</brief_title>
  <official_title>A Phase 1/2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the advantages of autologous stem cell transplantation (ASCT) over conventional&#xD;
      chemotherapy,1,2 the results of high-dose chemoradiotherapy in multiple myeloma (MM) are&#xD;
      still unsatisfactory with a 6-year event free survival (EFS) of only 24%.&#xD;
&#xD;
      Based on existing data, bortezomib-containing regimens are currently accepted at many centers&#xD;
      as an induction treatment option for patients with symptomatic MM, particularly if it is&#xD;
      planned to offer subsequent high-dose therapy with ASCT. So we will use bortezomib-containing&#xD;
      regimens as induction prior to this novel conditioning regimen. The objective of the present&#xD;
      study is to compare the toxicity and therapeutic efficacy of a new high-dose regimen using&#xD;
      dose-escalation of BOR, BU and MEL for ASCT in the Korean patients with MM. The patients&#xD;
      should be treated with bortezomib-containing regimens as an induction therapy before ASCT. We&#xD;
      will specifically analyze (i) the efficacy of the conditioning regimen in improving the&#xD;
      pre-ASCT status, response rate (ii) engraftment and transplant-related mortality (TRM) and&#xD;
      (iii) the impact on survival including progression-free survival (PFS) and overall survival&#xD;
      (OS).&#xD;
&#xD;
      Triple combination of conditioning will enhance the response rate after ASCT, and will&#xD;
      improve not only PFS, but also OS. We think that data from this study may further strengthen&#xD;
      feasibility of BOR in conditioning prior to ASCT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximally tolerated dose (Phase 1)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR and near CR (Phase 2)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Busulfan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Melphalan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib i.v. 0.7, 1.0 and 1.3 mg/m²/day</description>
    <arm_group_label>Busulfan</arm_group_label>
    <arm_group_label>Melphalan</arm_group_label>
    <other_name>VELCADE®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a confirmed diagnosis of multiple myeloma (MM)&#xD;
&#xD;
          -  Symptomatic MM (multiple myeloma with related organ or tissue damage)&#xD;
&#xD;
          -  The MM patients with induction chemotherapy with bortezomib-containing regimens&#xD;
             (bortezomib±steroid±adrimycin)&#xD;
&#xD;
          -  The MM patients who performed the peripheral blood stem cell collection and&#xD;
             appropriate stem cell counts (CD34+ cells 2 x 106/kg).&#xD;
&#xD;
          -  Age 20-65 years&#xD;
&#xD;
          -  Performance status: ECOG (Eastern Cooperative Oncology Group) 0-2.&#xD;
&#xD;
          -  Patient has measurable disease, defined as follows: measurable disease is defined as&#xD;
             serum M-protein ≥ 1 g/dL or urine M-protein ≥ 200 mg/24 hours when the patients&#xD;
             started the primary induction therapy.&#xD;
&#xD;
          -  Cardiac ejection fraction ≥ 50 % as measured by MUGA or 2D ECHO without clinically&#xD;
             significant abnormalities&#xD;
&#xD;
          -  Adequate liver functions: - Transaminase (AST/ALT) &lt; 3 X upper normal value -&#xD;
             Bilirubin &lt; 2 X upper normal value&#xD;
&#xD;
          -  Adequate hematological function: Platelet count ≥ 75 x 109/L, hemoglobin ≥ 8 g/dL,&#xD;
             (Prior RBC transfusion or recombinant human erythropoietin use is allowed), absolute&#xD;
             neutrophil count (ANC) ≥ 1.0 x 109/L&#xD;
&#xD;
          -  A negative serum or urine pregnancy test prior to treatment must be available both for&#xD;
             pre menopausal women and for women who are &lt; 1 years after the onset of menopause.&#xD;
&#xD;
          -  Expected survival 6 months&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic AL amyloidosis, smoldering multiple myeloma or MGUS.&#xD;
&#xD;
          -  Patient with plasma cell leukemia (&gt; 20% plasma cells in the PB and an absolute plasma&#xD;
             cell count of at least 2000/μL)&#xD;
&#xD;
          -  Patients who received an extensive radiation therapy within 4 weeks&#xD;
&#xD;
          -  Patient is known to be Human Immunodeficiency Virus (HIV) positive.&#xD;
&#xD;
          -  Patient has known clinically active Hepatitis B or C.&#xD;
&#xD;
          -  Previous renal transplantation&#xD;
&#xD;
          -  Severe peripheral neuropathy (Grade 2 or higher as defined by National Cancer&#xD;
             Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0)&#xD;
&#xD;
          -  Any other malignancies within the past 5 years except curatively treated non-melanoma&#xD;
             skin cancer or in situ carcinoma of cervix uteri&#xD;
&#xD;
          -  Pregnant or lactating women, women of childbearing potential not employing adequate&#xD;
             contraception&#xD;
&#xD;
          -  Other serious illness or medical conditions i. Uncontrolled or severe cardiovascular&#xD;
             disease, including myocardial infarction, within 6 months of enrollment, New York&#xD;
             Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina,&#xD;
             clinically significant pericardial disease, or cardiac amyloidosis ii. History of&#xD;
             significant neurological or psychiatric disorders including dementia or seizures iii.&#xD;
             Active uncontrolled infection (viral, bacterial or fungal infection) iv. Active ulcers&#xD;
             detected at gastroscopy v. Other serious medical illnesses&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs or its ingredients (i.e.,&#xD;
             hypersensitivity to compounds containing boron or mannitol)&#xD;
&#xD;
          -  Concomitant administration of any other experimental drug under investigation, or&#xD;
             concomitant chemotherapy, hormonal therapy, or immunotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeon-Seok Eom, MD, Ph.D</last_name>
      <phone>82-31-1588-8110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University Gill Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Hoon Lee, MD, Ph.D</last_name>
      <phone>82-32-1577-2299</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Seok Kim, MD, Ph.D</last_name>
      <phone>82-2-2228-1972</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chul-Won Suh, MD, Ph.D</last_name>
      <phone>82-2-1688-7575</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeong-Chul Mun, MD, Ph.D</last_name>
      <phone>82-2-2650-5114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki-Hyun Kim, MD, Ph.D</last_name>
      <phone>82-2-1599-3114</phone>
    </contact>
    <contact_backup>
      <last_name>Seok-Jin Kim, MD, Ph.D</last_name>
      <phone>82-2-1599-3114</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Soo Yoon, MD, Ph.D</last_name>
      <phone>82-2-2072-2114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Ki Min, MD, Ph.D</last_name>
      <phone>82-2-2258-6053</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <last_update_submitted>June 1, 2013</last_update_submitted>
  <last_update_submitted_qc>June 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

